コンテンツへスキップ
Merck

382129

HIV Reverse Transcriptase, Recombinant, E. coli

liquid, ≥5,000 units/mg protein, Nuclease-free

別名:

HIV RT

ログインで組織・契約価格をご覧ください。

サイズを選択してください


この商品について

NACRES:
NA.54
UNSPSC Code:
12352202
テクニカルサービス
お困りのことがあれば、経験豊富なテクニカルサービスチームがお客様をサポートします。
お手伝いします
テクニカルサービス
お困りのことがあれば、経験豊富なテクニカルサービスチームがお客様をサポートします。
お手伝いします

製品名

HIV Reverse Transcriptase, Recombinant, E. coli, liquid, ≥5,000 units/mg protein, Nuclease-free

recombinant

expressed in E. coli

form

liquid

specific activity

≥10,000 units/mL
≥5,000 units/mg protein

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze

technique(s)

molecular cloning: suitable

foreign activity

Nuclease-free

shipped in

wet ice

storage temp.

−20°C

Quality Level

Application

HIV Reverse Transcriptase, Recombinant, E.coli has been used as a standard in reverse transcriptase activity assay.

Disclaimer

Toxicity: Standard Handling (A)

General description

Recombinant HIV reverse transcriptase expressed in E. coli. Catalyzes error-prone synthesis on DNA and RNA templates. Provides an excellent target for evaluating antiviral agents.

Other Notes

One unit is defined as the amount of enzyme that will incorporate 1.0 nmol of labeled dTTP into acid-insoluble material in 20 min at 37°C, pH 8.3.

Packaging

Please refer to vial label for lot-specific concentration.

Physical form

In 10 mM potassium phosphate, 1 mM DTT, 20% glycerol, pH 7.4.

Preparation Note

Following initial thaw, aliquot and freeze (-20°C).

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

保管分類

10 - Combustible liquids

wgk

WGK 1


試験成績書(COA)

製品のロット番号・バッチ番号を入力して、試験成績書(COA) を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Geraldine Vilmen et al.
mBio, e0275221-e0275221 (2022-01-12)
Infection of rhesus macaques with simian-human immunodeficiency viruses (SHIVs) is the preferred model system for vaccine development because SHIVs encode human immunodeficiency virus type 1 (HIV-1) envelope glycoproteins (Envs)-a key target of HIV-1 neutralizing antibodies. Since the goal of vaccines
Conformation of HIV-1 Envelope governs rhesus CD4 usage and simian-human immunodeficiency virus replication
Vilmen G, et al.
mBio, 13(1), e02752-e02721 (2022)
Identification of an antiretroviral small molecule that appears to be a host-targeting inhibitor of HIV-1 assembly
Reed JC, et al.
Journal of Virology, 95(3), 10-1128 (2021)
Bo Meng et al.
Cell reports, 35(13), 109292-109292 (2021-06-25)
We report severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike ΔH69/V70 in multiple independent lineages, often occurring after acquisition of receptor binding motif replacements such as N439K and Y453F, known to increase binding affinity to the ACE2 receptor and confer
Jonathan C Reed et al.
Journal of virology, 95(3) (2020-11-06)
Given the projected increase in multidrug-resistant HIV-1, there is an urgent need for development of antiretrovirals that act on virus life cycle stages not targeted by drugs currently in use. Host-targeting compounds are of particular interest because they can offer

グローバルトレードアイテム番号

カタログ番号GTIN
382129-500UCN04055977213140

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)